Zacks Investment Research upgraded shares of Evoke Pharma (NASDAQ:EVOK) from a hold rating to a buy rating in a research note published on Tuesday morning, Zacks.com reports. Zacks Investment Research currently has $1.00 price target on the specialty pharmaceutical company’s stock.
According to Zacks, “Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company’s lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. “
A number of other brokerages have also recently issued reports on EVOK. ValuEngine raised Evoke Pharma from a sell rating to a hold rating in a report on Thursday, August 1st. HC Wainwright reissued a hold rating on shares of Evoke Pharma in a report on Friday, August 9th.
Evoke Pharma (NASDAQ:EVOK) last issued its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.03. Equities analysts expect that Evoke Pharma will post -0.35 earnings per share for the current fiscal year.
An institutional investor recently bought a new position in Evoke Pharma stock. Citadel Advisors LLC acquired a new stake in shares of Evoke Pharma Inc (NASDAQ:EVOK) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 59,047 shares of the specialty pharmaceutical company’s stock, valued at approximately $37,000. Citadel Advisors LLC owned 0.25% of Evoke Pharma as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 5.50% of the company’s stock.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Further Reading: Why does a company issue an IPO?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.